Home › Mieloma multiplo › Tennessee
Studi clinici su Mieloma multiplo nello stato di Tennessee
32 studi su Mieloma multiplo cercano partecipanti presso sedi nello stato di Tennessee.
Città nello stato di Tennessee
Testo ufficiale dello studio (inglese)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, PLLC, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07518186A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07073547A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- SCRI Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Henry-Joyce Cancer Clinic, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Sarah Cannon Research Institute, Nashville
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05201781A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Sarah Cannon Research Institute, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07116616A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- SCRI Oncology Partners /ID# 278353, Nashville
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
In reclutamentoFase 2
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06297226A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- SCRI Oncology Partners, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07637578Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 ago 2026 · NCT06375044A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07681596A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT07227311MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Ascension St. Thomas Hospital, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
- e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT06152575A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Chattanooga
- GSK Investigational Site, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05714839Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 2
Età da 18 a 70 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT07485647A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- SCRI Oncology Partners, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT06292780A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Nashville
- Research Site, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Nashville
- Research Site, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT07764978A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 lug 2026 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Baptist Memorial Hospital /ID# 280677, Memphis
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 lug 2026 · NCT05650632Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Vanderbilt-Ingram Cancer Center (VICC), Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- SCRI Oncology Partners, Nashville
In reclutamentoFase 2
Età 19 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT06974786Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- TriStar Bone Marrow Transplant, Nashville
- Vanderbilt- Ingram Cancer Center, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- TriStar Centennial Medical Center, Nashville
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 mar 2026 · NCT04988555A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Local Institution - 0008, Nashville
- Tennessee Oncology, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 mar 2026 · NCT06153251cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 40 e oltre · Tutti i sessi · Aggiornato il 20 gen 2026 · NCT05366881CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2025 · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- SCRI Oncology Partners, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 giu 2025 · NCT06119685Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.